Quantitative models of in vitro bacteriophage-host dynamics and their application to phage therapy by Cairns, Benjamin J et al.
Quantitative Models of In Vitro Bacteriophage–Host
Dynamics and Their Application to Phage Therapy
Benjamin J. Cairns1, Andrew R. Timms2, Vincent A. A. Jansen3, Ian F. Connerton2, Robert J. H. Payne1*
1 School of Biological Sciences, University of Bristol, Bristol, United Kingdom, 2Division of Food Sciences, University of Nottingham, Sutton Bonington Campus,
Loughborough, United Kingdom, 3 School of Biological Sciences, Royal Holloway University of London, Egham, Surrey, United Kingdom
Abstract
Phage therapy is the use of bacteriophages as antimicrobial agents for the control of pathogenic and other problem bacteria.
It has previously been argued that successful application of phage therapy requires a good understanding of the non-linear
kinetics of phage–bacteria interactions. Here we combine experimental and modelling approaches to make a detailed
examination of such kinetics for the important food-borne pathogen Campylobacter jejuni and a suitable virulent phage in an
in vitro system. Phage-insensitive populations of C. jejuni arise readily, and as far as we are aware this is the first phage therapy
study to test, against in vitro data, models for phage–bacteria interactions incorporating phage-insensitive or resistant
bacteria. We find that even an apparently simplistic model fits the data surprisingly well, and we confirm that the so-called
inundation and proliferation thresholds are likely to be of considerable practical importance to phage therapy. We fit the
model to time series data in order to estimate thresholds and rate constants directly. A comparison of the fit for each culture
reveals density-dependent features of phage infectivity that are worthy of further investigation. Our results illustrate how
insight from empirical studies can be greatly enhanced by the use of kinetic models: such combined studies of in vitro systems
are likely to be an essential precursor to building a meaningful picture of the kinetic properties of in vivo phage therapy.
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Introduction
The problem of antibiotic resistance has rapidly increased in
recent years. Diseases that had previously been well-controlled are
again becoming serious threats to animal and public health in a
variety of contexts [1–3]. The recognition of antibiotic resistance
as a major health problem has led to renewed interest in
alternative antimicrobial therapies, including bacteriophage ther-
apy [4–6]. Phage therapy has many potential advantages over
traditional antibiotics, including specificity for the target organism,
an apparent lack of toxicity or immunogenicity associated with
lytic phage [7], and the relative ease with which naturally
occurring lytic phages can be isolated against particular organisms
and produced in quantity. (Phage therapy has steered clear of
using temperate phages due to their potential for carrying toxin or
antibiotic-resistance genes.) Despite these advantages, develop-
ment and adoption of phage therapy has been slow. Outside of
some former Eastern Bloc countries, few phages have been
developed as practical antimicrobials since the widespread
adoption of antibiotics [4], although there are some recent
exceptions, such as the Food and Drug Administration (FDA)
approval in 2006 of a cocktail of six phages for the control of
Listeria monocytogenes on ready-to-eat meats [8].
One reason for the slow implementation of phages as
antimicrobial agents might be that the paradigms associated with
antibiotic therapies cannot easily be transferred to phage therapies.
For instance, it has been predicted that certain threshold
phenomena, not normally encountered in the pharmacokinetics
and pharmacodynamics (PK/PD) of antibiotic therapies, are of
central importance in practical phage therapy [9–11]. It is
therefore important to develop a suitable theoretical framework
for understanding the non-linear kinetic properties of phages as
‘‘self-replicating pharmaceuticals’’ [9]. To this end, we test a PK/
PD model of phage–bacteria interactions against in vitro exper-
imental data for a low passage strain of Campylobacter jejuni together
with a virulent phage active against this strain.
There are several reasons why a C. jejuni-phage system is well-
suited for testing how PK/PD models fare against in vitro data.
First, as a human pathogen C. jejuni ranks amongst the major
causes of infective gastroenteritis (campylobacteriosis) in the UK,
USA and many other countries, and thus is of considerable public
health interest [12–14]. Second, campylobacteriosis is a zoonotic
disease, most commonly contracted following the consumption of
contaminated foodstuffs; phage therapy of poultry prior to
slaughter, or of meat prior to packaging, could potentially prevent
campylobacters from entering the food chain [15–17]. Phage
therapy against C. jejuni is therefore not only important in human
medicine but is also relevant to agricultural and veterinary
applications. Third, population dynamics of C. jejuni cultures are
similar to those of many other pathogenic bacteria, including the
rise of resistant bacteria following inoculation of susceptible
populations with phages. Resistance to phages readily arises in
susceptible in vitro cultures for most (if not all) kinds of bacteria, and
for C. jejuni has also been observed to arise in vivo in poultry [18].
The C. jejuni-phage system is therefore of broad relevance to the
nascent field of phage therapeutics.
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In this paper we demonstrate the existence of threshold
phenomena in experimental data from an in vitro C. jejuni-phage
system, and illustrate how an understanding of these thresholds
will be important in developing practical in vivo phage therapies.
We focus on estimating the key biological parameters which
control the threshold levels, and ask whether these parameters
might vary between cultures according to dosage of phage
treatments or otherwise between different experimental contexts.
We also focus on the role of resistant bacteria. Although resistance
to phages has long been an area of interest in basic phage biology
and ecology, it is rarely addressed in detail in phage therapy
studies despite being a major issue for practical phage therapeutics
[19]. Although the characteristics of in vitro phage–bacteria
interactions are likely to differ from those observed in vivo, we
view the testing of models of in vitro phage therapy to be a
necessary first step in understanding how PK/PD theory of phage
therapy can be applied in clinical and other in vivo settings.
Materials and Methods
In this section we first discuss the theory behind our model, then
the experimental materials and methods and finally the statistical
methodology by which we fit the model to the data.
Theory of phage–bacteria interactions
In phage therapy, the pharmacokinetics and pharmacodynam-
ics (respectively the effect of dosage on phage concentration and
the therapeutic effect of the phage) cannot be fully separated. The
pharmacokinetics and pharmacodynamics are fundamentally
interrelated because phages spread throughout bacterial popula-
tions much like epidemics spreading through macro-biological
populations: infecting susceptible bacterial cells, reproducing and
subsequently infecting other susceptible cells. As with epidemics,
the rate of phage growth is dependent on the host population, in
that the phage population can only increase when the bacterial
concentration is sufficiently high. Wiggins and Alexander [20]
investigated the existence of such a threshold bacterial concentra-
tion using experimental methods, finding that concentrations of
around 104 colony-forming units (CFU) mL21 were required for
phage growth on a range of bacterial hosts. Payne and Jansen [9]
later derived a formula for this threshold using a mathematical
model of phage–bacteria interactions and termed it the proliferation
threshold: the concentration that the bacterial population must
exceed in order for the total phage numbers to increase. Likewise,
there is a critical threshold in the phage concentration, the
inundation threshold, which is the minimum phage concentration
above which the bacterial population declines. The inundation
threshold has parallels in antibiotic therapy, but the proliferation
threshold is unique to self-replicating antimicrobial agents. Unlike
previous authors who have compared or fitted models to data for
phage–bacteria interactions [11,21–26], we focus on fitting the two
thresholds identified above and investigate whether single values
for these thresholds adequately explain the dynamics of the phage
and bacterial populations over a range of starting conditions.
It is also useful to introduce the concepts of active and passive
therapy. Active therapy requires ongoing replication of phage in
order that the phage concentration reaches or is maintained at
levels sufficient to control the bacteria; passive therapy is when the
initial dose and primary infection is by itself sufficient to reduce
bacterial numbers. The two modes are not mutually exclusive and
both can occur in the same treatment, for example where the
initial phage dose is large enough to suppress the bacterial
population and is maintained at that level by phage replication,
but it is useful to separate them conceptually. To understand the
basic kinetic properties of phage therapy one must appreciate that
active therapy can occur only when the concentration of bacteria
exceeds the proliferation threshold, and passive therapy can occur
only when the initial concentration of phage exceeds the
inundation threshold [27].
A kinetic model. It is reasonable to assume that in well-
mixed experimental systems, interactions between phage particles
and bacterial cells occur such that the rate of reaction between any
two species is proportional to the product of their concentrations
(i.e. mass-action kinetics). These assumptions lead to a model
similar to that of Payne and Jansen [9]. That model, however, only
focused on the dynamics of phage infection during the initial
period of exponential growth of bacteria, and therefore did not
include bacterial resistance to phages. In order to extend the
analysis of phage–bacteria interactions beyond this short time-
scale, we allow that some bacteria may become insensitive to
infection, for example by acquiring resistance to the phage.
Dealing with resistance is a problem that will be central to the
design of phage therapies, because resistant mutants are highly
likely to be present in bacterial populations of any size much
greater than the inverse of the mutation rate. Our approach yields
a system of delay differential equations, where the concentrations
of susceptible and resistant bacteria, infected cells and free phage
particles at time t are S, R, I and V, respectively:
dS
dt
~aS{fS{bSV ,
dR
dt
~aRzfS,
dI
dt
~bSV{bS t{Kð ÞV t{Kð Þ,
dV
dt
~hbS t{Kð ÞV t{Kð Þ{bSV{mV :
ð1Þ
Here, both susceptible and resistant bacteria grow asynchro-
nously at a constant rate a per cell, which takes into account both
Author Summary
Phage therapy is an antimicrobial treatment based on
specific viruses which are natural predators of bacteria.
This approach is being promoted as a possible alternative
treatment for use against antibiotic-resistant strains of
bacteria. Despite its long history and many potential
benefits, adoption of phage therapy has been retarded by
a variety of factors, including a poor understanding of the
therapeutic consequences of the phage–bacteria relation-
ship. In our work we bring together theory and data by
testing kinetic models of phage–bacteria interactions
against data for an important agent of human food
poisoning, Campylobacter jejuni. Our model explicitly
allows for resistant bacteria because these have not been
properly accounted for in previous phage therapy theory
but will be relevant to practical applications. The excellent
fit of our model to the data confirms the value of such
combined approaches and supports an interpretative
viewpoint based on critical density-dependent thresholds
that are not part of standard pharmacology. We also find
that phage activity appears to be dose-dependent, and we
speculate on possible causes for this. Our work illustrates
how mathematical models can considerably enhance
insights from empirical studies, as an important step in
advancing the understanding of phage therapy.
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replication and phage-independent death. Susceptible bacteria
may give rise to resistant mutants with probability f /a per
susceptible cell per generation, and thus f is the rate of mutation.
Infection of susceptible bacteria as a result of the binding of free
phage particles to bacterial cells and successful infection is treated
as if it occurs according to the principle of mass action, with rate
parameter b. After a fixed latent period K, infected cells are lysed,
at which time an average of h new phage particles are released into
the environment per infected cell. Thus, the dynamics at time t
depend not only on the concentrations of phages and bacteria at
time t, but also on the concentrations of free phage particles and
susceptible bacteria K units of time in the past, as represented by
the terms S(t–K) and V(t–K). These new phage particles repeat the
same life-cycle or are lost to the system by a process of random
degradation, occurring at rate m. The parameters are summarised
in Table 1.
In this formulation, resistant bacteria are assumed to be totally
resistant (and so there is no term for interaction with phages) and
resistance cannot be lost once acquired. We also assume that
resources are sufficiently plentiful for there to be no competition
between susceptible and resistant bacteria. Hence, the concentra-
tion of resistant bacteria is driven by, but does not affect the
concentration of, susceptible bacteria; consequently the presence
of resistant bacteria has no effect on the therapeutic action of
phages on susceptible cells (although it may affect the overall
therapeutic outcome).
Phage therapy. From the equation for dS/dt, the
concentration of susceptible bacteria can only decline if the
concentration of free phages exceeds the inundation threshold VI,
where
VI~
a{f
b
: ð2Þ
Thus if the initial concentration is above this inundation
threshold then active replication of phages is not essential to
therapy, and therapy can then be considered ‘passive’ in this sense.
In any case, it is a precondition of therapeutic effect that the phage
concentration eventually exceeds the inundation threshold VI.
Active therapy can then proceed only if the total number of phages
(free virions plus the phages that are latent in infected cells) is
increasing. This occurs only when the phages gained through
replication can replace those lost to degradation, or equivalently,
whenever the expected number of progeny produced by each
phage is greater than 1. The expected number of progeny per
virion (also known as the basic reproductive number) can be
calculated from Equation 1, resulting in the condition that the
total number of phages increases if hbS/(m+bS).1. Solving this for
the concentration of susceptible bacteria S, we find that the total
phage concentration increases when S exceeds the proliferation
threshold,
SP~
m
b h{1ð Þ : ð3Þ
Except for the mutation rate f, these thresholds are the same as
those from Payne and Jansen [10], because they relate only to the
concentration of susceptible bacteria. While therapeutic action is
predicated on the phage concentration eventually exceeding the
inundation threshold VI, the initial dosage is not necessarily
important as long as the bacterial concentration grows above the
proliferation threshold SP before too many phage particles
degrade. Thereafter, active replication of phages will bring the
phage concentration up above VI and the phage will have a
therapeutic effect.
The inundation and proliferation thresholds are of considerable
practical importance to phage therapy. Not only do they delimit
active and passive phage therapies and characterise the peculiar
properties of phages as antimicrobial agents, but they can also be
used to prescribe dosage and timing of a phage treatment so as to
achieve the greatest therapeutic effect [10,27]. One could infer the
physical parameters of phage–bacteria interaction (binding rate;
bacterial growth rate; latent period prior to lysis; burst size; phage
degradation rate) from data and use the model Equation 1 to
predict the outcomes of the joint population dynamics in vitro.
However, the inundation threshold VI and the proliferation
threshold SP encapsulate the primary information about the
therapeutic effect of a phage treatment. To help gain insight into
these thresholds we re-parameterise the model Equation 1 in terms
of VI and SP. Together, these parameters can replace the binding
rate b and the burst size h, which are difficult to estimate directly
and are also likely to differ in vivo, when phage treatments are
applied outside the laboratory, from those that are found in vitro.
(The parameters b and h can of course be found from VI, SP, a, f
and m by rearranging Equation 2 and Equation 3.) These two
threshold parameters are also summarised in Table 1.
Experimental methods
Propagation and enumeration of campylobacters and
bacteriophage. Campylobacter jejuni strains were routinely
Table 1. Definitions of model parameters for Equation 1.
Parameter Symbol Units
growth rate of bacteria a h21
binding rate of phages to susceptible bacteria b mL CFU21 h21
mutation rate of bacteria f h21
latent period (time between infection and lysis) K h
burst size at lysis h PFU
phage decay rate due to thermodynamic and other effects m h21
phage concentration above which susceptible bacteria decline VI PFU mL
21
bacterial conc. above which phage replication exceeds phage loss SP CFU mL
21
Fitted values for these parameters are given in Table 2 and Table 3.
doi:10.1371/journal.ppat.1000253.t001
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propagated on blood agar base no. 2 (Oxoid Ltd., Basingstoke,
United Kingdom) supplemented with 5% defibrinated horse blood
(Oxoid) for 24 h under microaerobic conditions (5% O2, 10%
CO2, 85% N2) at 42uC. C. jejuni were enumerated using
Campylobacter blood-free selective agar base (Oxoid). Campylobacter
bacteriophage CP8 [16] was routinely propagated on strain
NCTC 12662 (phage type 14; PT 14), however, bacteriophages
from interaction experiments and bacteriophage decay
experiments were enumerated on host lawns of C. jejuni strain
HPC5 [16].
Bacteriophage decay experiment. To determine the rate
of decay of free phage in the absence of a host, bacteriophage CP8
was added to 50 mL of nutrient broth no. 2 (Oxoid) in 100 mL
conical flasks and incubated at 42uC under microaerobic
conditions with shaking at 100 rpm. Samples were taken for up
to 168 h and bacteriophages enumerated as above.
Campylobacter and bacteriophage binding
experiments. To assess the latent period and burst size of a
single round of phage replication, Campylobacter jejuni strain GIIC8
was grown and inoculated into 50 mL of nutrient broth no. 2
(Oxoid) in 100 mL conical flasks as previously described. The
triplicate cultures were grown to late log phase, approximately 8.3
log10 CFU mL
21, at which point CP8 was added to an
approximate MOI of 0.01. Incubation with shaking was
continued and samples of the culture removed at various time
points, up to 2 h post phage addition. Samples were filtered to
remove Campylobacter cells and bound phages. Unbound ‘free’
phages were titrated as described previously.
Campylobacter and bacteriophage interaction
experiments. Campylobacter jejuni strain GIIC8 [16] was grown
on blood agar plates for 24 h as described above. Cells were
collected into phosphate buffered saline and OD600 readings
taken. GIIC8 was added to 50 mL of nutrient broth no. 2 (Oxoid)
in 100 mL conical flasks to a final concentration of 5 log10 colony-
forming units (CFU) mL21 and incubated at 42uC under
microaerobic conditions with shaking at 100 rpm. At 2 h post
inoculation, bacteriophage CP8 was added to a final concentration
of 5 log10 plaque-forming units (PFU) mL
21, 6 log10 PFU mL
21
or 7 log10 PFU mL
21 to give approximate multiplicities of
infection (MOI) of 1, 10 or 100. Samples were taken every 2 h
for 24 h. Each aliquot was serially diluted and campylobacters
enumerated as described above. Bacteriophages were enumerated
as above following passage of the cell suspension through a 0.2 mm
Minisart filter (Sartorius AG, Go¨ttingen, Germany) to remove the
Campylobacter cells.
Statistical methods
Counts of bacterial colonies or phage plaques were assumed to
be Poisson distributed with a mean count given by the true
concentrations of bacteria or phages divided by a known dilution
factor. Model parameters were optimised for the phage decay data
(phage decay rate m) in a generalised linear model (GLM) fitted by
iteratively re-weighted least squares [28], with initial parameter
estimates chosen automatically by the glm algorithm in the R
statistical computing environment.
For the binding assay (all parameters except the mutation rate f)
and interaction data (all parameters), the non-linear model given
by Equation1 was fitted using a generalised non-linear model
(GNLM). Starting values for initial phage and bacterial concen-
trations were estimated for each culture as the mean concentra-
tions at time 2 h. Initial parameter values were selected by hand
and then estimated parameters were found using a variant of
simulated annealing [29] followed by the ‘L-BFGS-B’ quasi-
Newton algorithm [30]. Two optimization algorithms were used to
attempt to ensure that the fitted parameters did not get stuck at a
spurious local optimum. J.K. Lindsey’s gnlm package for R was
modified to use the function optim, which implements above-
mentioned optimisation routines, and was used to perform the
fitting procedure [31].
In the case of the interaction data, the model was re-
parameterised in order to focus on the aspects of most relevance
to phage therapy. The proliferation threshold SP and the
inundation threshold VI together replaced the binding rate b and
the burst size h according to Equation 2 and Equation 3.
Approximate starting parameter values were chosen as follows.
Rough starting values for the threshold parameters and for the
bacterial growth rate a were obtained by inspection of the plotted
data. The starting values of the phage decay rate m were taken
from the analysis of the phage decay data, and the starting values
for the latent period K and burst size h were obtained from the
analysis of the binding assay data. A mutation rate f of 1026 h21
was selected as a starting value by inspecting the data and
extrapolating back to obtain the approximate ratio of resistant to
susceptible cells in the exponential phase; this rate is faster than
would be typical for point mutations. Observations at time 0 h
were omitted because they suggested an initial lag phase prior to
exponential growth of bacteria that is beyond the scope of the
model Equation 1. Data for the two cultures in which phages were
not present were additionally truncated at 12 h to confine
observations to the exponential period of growth; in these cultures
the bacterial populations appeared to enter stationary phase
shortly after 12 h.
Although in principle it is possible to examine the fit of any
model by an approximate test of the significance of the model
derived from analysis of deviance tables, and to compare models
by use of likelihood ratio tests, in a statistical context models like
Equation 1 may violate the assumptions of likelihood ratio
methods and admit such a wide range of population dynamics
that the overall model is unlikely to be rejected [22]. Instead, we
compare model variants by use of the Akaike Information
Criterion (AIC) [32–33], a quantity derived from information
theory that may be used to compare models with different
numbers of parameters. (The AIC is defined as the negative of
twice the log-likelihood of the fitted model, plus a penalty defined
as twice the number of free parameters in the model. Values of the
AIC for competing models can be compared to judge which
provides a better fit: lower values of the AIC indicate a closer fit to
the data.)
Results
Bacteriophage decay experiment
The phage decay experiments suggest that in the absence of
bacteria, phage virions degrade at a roughly constant rate, such
that the concentration of phages declines linearly on a log-linear
plot (Figure 1). The rate of phage degradation fitted by GLM is
m=1.06261022 h21 (95% CI 0.96161022–1.16561022), with
fitted initial phage concentrations of between 5.016105 and
6.326105 PFU mL21. The null deviance (including distinct
intercept terms for each culture but no decay term) is 514.79 on
60 degrees of freedom, and the residual deviance for the phage
decay GLM is 80.01 on 59 degrees of freedom.
Campylobacter and bacteriophage binding experiments
Binding assays show a steep decline in the concentration of free
phages due largely to binding of free phages to susceptible
bacteria, followed by a rapid, somewhat synchronised increase in
this concentration as a second generation of phages is released by
Quantitative Phage Therapy Modelling
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lysis of infected cells (Figure 2). This series of observations of phage
concentrations comprises a single round of phage replication. The
fitted parameters of interest are the latent period K=1.312 h and
the burst size h=1.957 virions per cell. Other fitted parameters are
‘nuisance’ parameters in the analysis of this data, because they are
closely correlated and hence are liable to be inaccurate. Their
values are the bacterial growth rate a=0.272 h21, the binding rate
b=8.02861028 h21 and the phage decay rate
m=1.03261022 h21. Fitted initial phage concentrations varied
between 2.766106 and 2.846106 PFU mL21, while fitted initial
bacterial concentrations varied between 2.686107 and
3.036107 CFU mL21.
Campylobacter and bacteriophage interaction
experiments
Data from phage–bacteria interaction experiments show a
regular pattern: exponential growth of bacteria followed after
some time by rapid phage proliferation; a sudden crash in the
bacterial population and the slowing of phage growth; finally, the
resurgence of exponentially-growing bacteria that do not appear to
be susceptible to the phage (Figure 3). Overall, the model Equation
1 provides a good fit to these data, both where model parameters
are treated as common to all cultures (the ‘common-parameter’
model; Table 2) and where they are allowed to vary between
cultures (the ‘varying-parameter’ model; Table 3). These fitted
models match very well to the observed phage and bacterial
concentrations up to the end of the crash in the concentration of
susceptible bacteria and the beginning of the growth of
(apparently) resistant bacteria around 14–16 h (Figure 3). Beyond
that time there is a pattern of exponentially-growing bacteria
despite a high phage concentration. This is reflected in the model,
but there is a greater discrepancy between the fitted and observed
values. The difference between the AIC values for the ‘varying-
parameter’ model (AIC<4948.1) and the ‘common-parameter’
model (AIC<5765.5) is very large (<817.4), indicating that the
former provides a much better fit to the data.
The roles of some parameters in the model are of particular
interest, and were examined by re-fitting the common-parameter
model with these parameters set to 0. Some form of resistance to
phages is an essential component of any model that can fit the
pattern of bacterial and phage growth followed by the crash and
resurgence of the bacterial population observed for this system. A
variant of the common-parameter model without resistance (i.e.
with mutation rate f=0) is unable to fit the data after the steep
decline in the bacterial concentration and provides a very poor fit
over the entire time series (AIC<27571). Conversely, the
common-parameter model has an unrealistically small fitted value
of the latent period K between infection and lysis. Nonetheless, the
non-zero latent period of the common-parameter model gives a
substantially better fit, compared to the model with K=0
(AIC<6139).
Discussion
Thresholds
The inundation and proliferation thresholds help define two
modes of phage therapy (passive and active) as well as the success
or failure thereof, and can be used to gain insight into the kind of
information required to develop practical treatment protocols.
Our time series clearly show an inundation threshold; the bacteria
grow readily in the presence of a virulent phage until the phage
reaches a critical concentration beyond which susceptible bacteria
rapidly become infected. The effect of crossing a proliferation
threshold is more difficult to observe directly, in part due to the
fact that it is a threshold for the increase of total phage but not
necessarily for free phage. For example, in the binding assays
(Figure 2), although the bacterial concentration is very high the
concentration of free phage does not appear to increase relative to
the initial concentration at the first round of replication. The
Figure 1. Phage decay in the culture medium in the absence of
hosts. The plot shows data from one of the three cultures in the phage
decay experiment, with observed concentrations in log10 PFU mL
21
(points) and the fitted curve log10 V(t) = log10 V02mt (line). The phage
concentration declines linearly on log-linear axes, indicating approxi-
mately exponential decay with estimated rate 1.06261022 h21.
doi:10.1371/journal.ppat.1000253.g001
Figure 2. Binding of phages to bacterial hosts and the
subsequent release of phage at lysis of infected cells. The plot
shows data from one of the three cultures in the binding assay, with
observed concentrations of free phages in log10 PFU mL
21 (points) and
the fitted curve V(t) (line), derived from Equation 1. Lysis of infected
hosts is well synchronised at approximately 1.3 hours, although this is
exaggerated by the fitted curve. The phage concentration does not
appear to increase, which is consistent with the low estimate for the
burst size (approximately equal to 2 virions).
doi:10.1371/journal.ppat.1000253.g002
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interaction experiments (Figure 3) do, however, show a clear
change from a slow decline to a rapid increase in the phage
concentrations after a period that appears to be independent of the
initial phage concentration and is much longer than the delay
between infection and lysis of individual cells. One could attempt
to estimate the proliferation threshold from time series data ‘by
eye’, without recourse to complicated statistical methods. Such
estimates would be very imprecise, partly because they depend on
the delay in the response of the phage population to a change in
the bacterial population. We therefore used a formal statistical
procedure to estimate the values of both the inundation and
proliferation thresholds, using visual estimates as starting values
only. We have shown that our model provides an excellent fit to
the data, and this is consistent with the threshold-based view of
phage–bacteria interactions.
The values of these thresholds and other model parameters will
differ in vivo, and indeed in other in vitro contexts. Nonetheless, our
results also have implications for future experimental and clinical
protocols for phage therapy. Two predictions regarding the dose of
a phage inoculum can be derived from the model that are also
reflected in the interaction data presented above. First, at lower
doses the response of a bacterial population of a given size to a
phage will vary little with the dosage of a phage inoculum. The
phage concentration will not exhibit net growth unless the host
concentration is above the appropriate proliferation threshold, and
when this occurs phage proliferation becomes relatively rapid until
the phage concentration reaches the inundation threshold and
begins to suppress the host population (phage therapy in an active
mode). Thus a wide range of initial phage doses should suppress
the bacterial population at roughly the same time; this might be
particularly important where the timing of phage therapy is
relevant, such as in agricultural or food safety contexts. Second, at
higher doses—those close to or greater than the inundation
threshold—the effect of a phage on the bacterial population will
change rapidly as the dosage increases. As the initial phage
concentration is increased beyond the inundation threshold, the
growth rate of the bacterial population will quickly shift to an
exponential decline. In cases where the phage concentration starts
Figure 3. Data from interaction experiments together with fitted curves obtained by maximum likelihood estimation. Concentrations
of C. jejuni (circles; black) and phage (triangles; red) vary together in a way consistent with the threshold theory of phage-bacterial interactions. Fitted
models in which parameters are either common to all (dashed) or allowed to vary between cultures (solid). Panels (A–H) correspond to cultures 1–8,
respectively, with fitted parameters as given in Table 2 and Table 3.
doi:10.1371/journal.ppat.1000253.g003
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substantially above the inundation threshold, phages can be
expected to infect all susceptible host cells in a relatively short
period of time (phage therapy in a passive mode).
Resistant bacteria
Although molecular and evolutionary questions relating to
phage resistance have been addressed in detail in the past
(reviewed in [19]), as far as we are aware this is the first phage
therapy study in which models that incorporate acquisition of
resistance have been fitted directly to in vitro time series data. The
advantage of this approach to considering the rise of resistant cells
in a phage therapy context is that it provides a more practical
assessment of the role that resistant cells might play. The threshold
theory of phage therapy implies that the growth of resistant
bacteria and the physical properties required for apparent
resistance are very sensitive to environmental conditions and
phage concentrations; in some cases, cells that are only slightly less
susceptible than the wild-type can grow when the wild-type cannot
[19]. Thus, it is nearly impossible to directly compare the
outcomes of batch cultures (let alone in vivo or other practical
trials of phage therapies) and other tests where the purpose of the
comparison is to understand the role of resistance in phage
therapies. Although we fit the rate at which resistant cells arise by
mutation from a susceptible population, the definition of
‘resistance’ is specific to the conditions that persist in these
cultures. Instead, the focus here is on understanding the qualitative
role that resistant bacteria may play in phage therapy.
A particular feature of the interaction data is the resurgence of
bacteria after the phage-induced crash of the susceptible
population. Some form of resistance—whether due to point
mutation or other processes—seems necessary to explain this
pattern, and it appears to be heritable or transmissible because the
concentration of apparently-resistant bacteria continues to grow in
the presence of high concentrations of phages. These resistant
bacteria exhibit several other interesting features. First and, from a
therapeutic perspective, most importantly, the rate of growth of
the resistant bacteria is approximately the same as that of the
original, susceptible population, indicating that there is little or no
fitness disadvantage to the apparently-resistant cells under the
conditions of these in vitro experiments. Previous studies have
found a reduction in fitness of phage-insensitive campylobacters in
the gut of broiler chickens when phages are absent, evidenced by a
decrease in colonization efficiency [18]. Although our result might
be specific to the in vitro context of our experiments, it is
unreasonable to assume that significant fitness disadvantages will
be incurred under all environmental conditions. Whether resistant
Table 3. Model parameters from Equation 1 where parameters are allowed to vary between cultures, fitted to data from the
interaction experiments.
Model parameters (varying-parameter model)
MOI Culture Initial conditions Parameters
log10 S0 log10 V0 a log10 f log10 b h K m log10VI log10SP
0 1 4.726 — 0.8545 — — — — — — —
2 4.862 — 0.9028 — — — — — — —
1 3 4.742 4.888 0.9738 25.675 25.561 2.080 0.8563 0.0067 5.550 3.353
4 4.906 4.627 0.8608 24.940 25.931 1.624 0.4314 0.0009 5.866 3.096
10 5 4.929 5.837 0.8781 25.017 26.738 1.795 0.5563 0.0022 6.682 4.190
6 4.844 5.821 1.0614 26.508 26.468 1.840 0.6005 0.0033 6.494 4.063
100 7 4.531 6.844 0.9679 25.459 27.180 3.023 0.9168 0.0416 7.166 5.493
8 5.024 6.707 0.8975 25.172 27.322 2.366 0.5004 0.0107 7.275 5.218
Estimates were obtained by maximum likelihood as described in the text; parameter notation is as in Table 1. The total AIC for this model is 4948.075. There is a strong
positive relationship between the logarithm of the initial phage concentration and the logarithms of the inundation threshold VI and proliferation threshold SP, which
together indicate dose-dependence of the binding rate b.
doi:10.1371/journal.ppat.1000253.t003
Table 2. Model parameters from Equation 1 where parameters are common to all cultures, fitted to data from the interaction
experiments.
Fitted parameters (common-parameter model)
a log10 f log10 b h K m log10VI log10SP
0.8604 24.9875 27.2310 1.5501 0.0944 0.0003 7.1657 4.0309
Initial conditions
MOI 0 1 10 100
Culture 1 2 3 4 5 6 7 8
log10 S0 4.7142 4.9509 4.4892 4.5580 4.6689 4.5432 4.5428 5.0803
log10 V0 — — 4.7154 4.7903 5.6328 5.7673 6.5282 6.4301
Estimates were obtained by maximum likelihood as described in the text; parameter notation is as in Table 1. The total AIC for this model is 5765.540.
doi:10.1371/journal.ppat.1000253.t002
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cells have reduced pathogenicity is an important question for
future study. Second, in each culture from the interaction
experiments that includes the phage, the resistant bacteria appear
at roughly the same time, although there are too few cultures to
expect much variation in this quantity and in any case all cultures
were inoculated with samples from the same source population.
The fitted rate of mutation to resistance, f, is of the order of
1025 h21, which is relatively fast, but might be consistent with
hyper-mutability of some individuals, with more complex genetic
(or epigenetic) phenomena such as recombination (known to be a
mechanism by which resistance is acquired in other strains of C.
jejuni; [18]) or phase variation [34–36], or with a combination of
different types of resistance. Tracing the resistant population back
to the beginning of the experiment, it is apparent that an
alternative explanation is that a very small number of resistant cells
were present in each culture at the start of the experiment,
although this also suggests a high rate of mutation to resistance
that might be explained as above.
The assumption that bacteria are either susceptible or totally
resistant is adequate to explain most of the variation in the data,
but there are some discrepancies. One of the chief discrepancies is
that the phage concentration does not simply reach a peak then
slowly decline, as suggested by the fitted curve. Instead, there
appears to be a second peak, appearing some hours after the first
(Figure 3, panels C–H, at around 20 hours). It is possible that this
phenomenon is artefactual, but it is beyond the scope of the simple
model to predict such dynamics. Possible interpretations of this
phenomenon include more than one type of resistant sub-
population, the mutation of phages to infect resistant bacteria
[19,37], or possible coexistence dynamics of phages and
susceptible bacteria [38–40]. Critically, the threshold-based model
implies that even a partially-resistant sub-population of bacteria
could be responsible for the recovery of the bacterial concentra-
tion, provided only that its inundation threshold is sufficiently
larger than that of the original susceptible population and than the
phage concentration following the crash. The possibility that such
partially-resistant cells might be responsible for resurgence of
bacterial populations highlights the need for a threshold-based
understanding of phage–bacteria interactions for phage therapy.
Cells that are resistant to a phage should be expected to be
found with a high probability in bacterial populations above a
certain size, and phage therapy is by its nature a strongly selective
treatment. Therefore, resistance must be taken into account in
both theoretical and empirical studies of phage therapies [19,37].
This is not to say that the likelihood of resistance is an
insurmountable problem for phage therapy, even if in some cases
it might not be possible to avoid it. In the context of in vivo control
of campylobacters in poultry, achieving a reduction in C. jejuni load
at the time of slaughter could reduce campylobacter numbers on
retail poultry products [16] and hence the incidence of human
campylobacteriosis [41]. Optimising the dosage and timing of the
phage treatment would then be sufficient to avoid problems with
resistant bacteria. In other contexts, it may be necessary to take
measures to suppress resistant bacteria, for example by use of a
cocktail of phages that bind to different receptors.
Differences between cultures
The common-parameter model (Table 2), in which the model
parameters are assumed to be the same for all cultures, appears to
provide a good fit to the data (Figure 3). But by allowing model
parameters to vary between cultures the fit is substantially
improved. The purpose of allowing these parameters to differ is
to investigate how the model of Equation 1 might deviate from the
true dynamics of the C. jejuni-phage system. The varying-
parameter model shows a specific trend in the fitted values of
the inundation threshold VI and the proliferation threshold SP
(Table 3). As the initial phage concentration increases, fitted values
of both thresholds also increase; the relationships are roughly
linear in the logarithms of each of these parameters. Under the
assumptions of the model, this implies that the binding rate b
declines with increasing initial concentration of phages; there are
no other strong relationships between fitted parameters (Table 3),
although the burst size h and the phage decay rate m are slightly
larger in cultures 7 and 8, which have the highest initial phage
concentrations. The fitted phage decay rates are otherwise similar
to those found in the decay experiment and binding assay. A
similar trend in the binding rate with respect to initial phage
concentration was observed by Mudgal et al. [24] in interactions
between phage and Leuconostoc species, which are used in the
fermentation of sauerkraut (and for which phages are a pest, rather
than a therapeutic agent). It is important to note that this trend in
the fitted values of b may either represent true differences between
cultures in the effective binding rates, or mask other differences
between cultures that are not included in the model but which are
best approximated by the fitting algorithm with a change in b.
A wide range of phenomena might plausibly explain the decline
in the fitted binding rate b as the initial concentration of the phage
increases. Such explanations include restriction-modification
systems [42] or other responses by the bacterial population to
the presence of phages, the contribution to the loss of free phages
due to unproductive binding of phage particles to resistant bacteria
or debris from lysis [38] or the superinfection of already-infected
cells and possible subsequent lysis inhibition [43]. These
phenomena could play a substantial role in the success or
otherwise of phage therapies but are difficult to assess from time
series data such as ours. Although their microbiological and
ecological implications are well-studied, more work is needed to
assess their practical importance for phage therapies.
Another possibility is phenotypic diversity in the phage or host
populations, due to genotypic or physiological differences between
individuals in the initial populations and subsequent selective
effects. For instance, it is possible that phages from the original
stock are less effective at binding to the GIIC8 strain of C. jejuni.
Alternatively, the phage preparation may contain defective
interfering particles, which are unable to replicate by themselves
and can interfere with the replication of functional viruses when
they co-infect [44], or other non-infective virus particles that could
competitively exclude functional phage particles from their
binding sites on susceptible cells. In these cases, the larger the
size of the phage inoculum the greater the proportion of the
original stock that makes up the phage concentration at any given
time and the lower the effective binding rate.
The inundation threshold may vary if there is heritable
variation in the binding rate or in the susceptibility to successful
infection after binding. In this case, a large initial phage
concentration could selectively enrich the more-resistant bacteria.
Consequently, the average susceptibility of the bacterial popula-
tion at its peak concentration will be lower than would otherwise
be the case, and so the apparent inundation threshold will be
higher. It is difficult, however, to assess the magnitudes of such
effects in the absence of detailed information about the genetic
diversity of the phage populations.
Whatever the underlying biological mechanisms, it is plausible
that trends in the inundation and proliferation thresholds or the
binding rate could also play a role in vivo. If trends similar to those
we have found here were found in vivo, it might imply that there is
a non-trivial optimal dose, yielding the fastest and most effective
suppression of the bacterial population, when a phage therapy is
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administered in an active mode. Further, the dose required to
inundate bacteria with phages in a passive therapy might be
inflated, relative to the concentration that suppresses bacteria
following active proliferation, due to increased inundation
thresholds. Overall, aspiring phage therapists should be aware
that such trends are consistent with in vitro data, and that dose-
dependent changes in threshold phenomena might be observed in
therapeutic contexts.
The latent period
A comparison may be made between the interaction experi-
ments (which are designed to show the overall dynamics of phage–
bacteria interactions) and the phage decay experiment and the
binding assay (which focus on particular parameters). The latent
period K is of particular interest here. The value of K fitted to the
data from the binding assay is approximately 1.3 h (corresponding
to the minimum concentration of the fitted curve; Figure 2), while
the values of K fitted to the data from the interaction experiment
are between about 0.5 h and 0.9 h where the parameters may vary
between cultures, and less than 0.1 h for the common-parameter
fitted model. There is no apparent relationship between the values
of K in the varying-parameter model and the initial concentration
V0 of phages, but there does appear to be a relationship with the
initial concentration S0 of bacteria. But, since the fitted values
differ substantially from the quantity which is more directly
observed in the binding assay, it seems unlikely that there is a
biological reason for such a close relationship between the fitted
values of the latent period and the initial bacterial concentration.
In any case, all of these fitted values of the latent period K are
much shorter than the period before rapid proliferation of phage
observed in the interaction data (Figure 3, panels C–H),
supporting the interpretation of the delay before rapid phage
growth as evidence of a proliferation threshold.
Although the latent period plays an important role in the life
cycle of individual phage particles, the model Equation1 suggests
that the latent period may not always be as important as other
parameters in determining the overall dynamics of phage–bacteria
interactions. The phage life-cycle may be divided into the time
spent between hosts, ending when the free phage binds to a
susceptible cell, and the latent period between infection and lysis.
The time spent between hosts has mean duration 1/bS, for binding
rate b and concentration S of susceptible bacteria, while the latent
period between infection and lysis is given by the parameter K.
Because b is very small, only when the population of susceptible
bacteria is large will the latent period be an appreciable fraction of
the total life-cycle duration (1/bS+K). For values of b around
1026 ml CFU21 h21 and K equal to about 1 h, the concentration
S of susceptible bacteria would have to be close to 106 CFU mL21
in order for the latent period to contribute a large portion of the
total life-cycle time. But the observed concentration of susceptible
bacteria is only in this range for a fraction of the duration of the
interaction experiment before the bacterial population crashes
(Figure 3), and thus this experiment may contain relatively little
information about the latent period. Over most of the time series
of interaction data, the phage dynamics are primarily determined
by the binding rate b, the burst size h and the decay rate m, but not
the latent period K. Moreover, because the phage growth rate is
also determined by the burst size h, the fitting procedure can trade
K off against h or other parameters to obtain a good fit even if K is
inaccurate. (This is a statistical trade-off; there may also be a fitness
trade-off for phage between latent period and burst size [45] but
we do not address such evolutionary issues here.) We tested the
capability of the model to fit the data when the latent period K was
set to 0. Although a non-zero latent period provides a substantially
better fit according to the AICs, there is less of a difference
between the main common-parameter model and its K=0 variant
than there is between the common-parameter and varying-
parameter models. This further indicates that, at least in some
cases, the dynamics of phages and bacteria are not strongly
sensitive to the latent period.
Conclusions
Despite their long history, phage therapies are still far behind
chemical antibiotic therapies in both theory and practice. If phage
preparations are to fulfill their promise as self-replicating
antimicrobials, an understanding of the kinetics unique to
phage–bacteria interactions must be developed and applied in a
therapeutic context. Recent years have seen renewed attention
given to models of these interactions, and lately to validating
predictions from such models with data from a variety of bacterial
species and virulent phage strains. It should be anticipated that
any simple model for phage–bacteria interactions will not capture
all aspects of a particular combination of phage and bacterial
strains, but it is important that models used in designing a phage
treatment do provide accurate predictions of parameters such as
the inundation and proliferation thresholds. To date, much of the
study of phage–bacteria interactions has been grounded in pure
rather than applied concerns, and recent models have tended to
focus more on ecological and evolutionary issues than on the
effectiveness of a particular phage treatment in controlling a
bacterial population. As we have attempted to do here, these
approaches would benefit from being recast in terms relevant to
phage therapy in order that they may contribute constructively to
advancing therapeutic goals. Models examined in this way and
tested against empirical data can then provide considerable insight
into therapeutic issues.
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